IBM Watson Health partners with MIT, Harvard on 5-year cancer initiative

IBM Watson Health partners with MIT, Harvard on 5-year cancer initiative

IBM Watson Health and the Broad Institute of MIT and Harvard have launched a five-year $50 million research project to delve into cancer drug resistance. Researchers will study thousands of drug-resistant tumors and draw on Watson’s computational and machine learning methods to understand how cancers become resistant to therapies. Drug resistance is a major cause of nearly 600,000 annual cancer deaths in the United States alone.  In a limited number of cases, scientists have discovered the cause of drug resistance, allowing the development of new drugs to overcome it. In most cases, however, the causes of drug resistance are not fully understood. While a growing number of cancer treatments can hold cancers in check for months or years, most cancers eventually recur. To help understand how cancers become resistant to…


Link to Full Article: IBM Watson Health partners with MIT, Harvard on 5-year cancer initiative